{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:08:00Z","timestamp":1792804080406,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jbo.2022.100459","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:10:14Z","timestamp":1666984214000},"page":"100459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Francesco","family":"Pantano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Tramontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Iuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Leanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Piccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Paviglianiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umile Giuseppe","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocky","family":"Strollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2022.100459_b0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Marincola FM Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.jbo.2022.100459_b0010","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbo.2022.100459_b0015","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Srinivas S et al Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbo.2022.100459_b0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbo.2022.100459_b0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Hellmann MD Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbo.2022.100459_b0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2019.09.022","article-title":"Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors","volume":"123","author":"Vozy","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jbo.2022.100459_b0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.03.002","article-title":"Immune checkpoint inhibitor-associated hypophysitis World Health Organisation VigiBase report analysis","volume":"113","author":"Guerrero","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jbo.2022.100459_b0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Ad-verse Event Reporting System","volume":"14","author":"Raschi","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.jbo.2022.100459_b0045","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","article-title":"De Ponti F Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. Food and Drug Administration adverse event reporting system","volume":"11","author":"Raschi","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2022.100459_b0050","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jbo.2022.100459_b0055","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.33592","article-title":"Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis","volume":"149","author":"Filippini","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jbo.2022.100459_b0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000431091","article-title":"Immunology of osteoporosis: a mini-review","volume":"62","author":"Pietschmann","year":"2016","journal-title":"Gerontology"},{"key":"10.1016\/j.jbo.2022.100459_b0065","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bone.2008.02.017","article-title":"Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis","volume":"43","author":"D'Amelio","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2022.100459_b0070","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2353\/ajpath.2006.060180","article-title":"B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease","volume":"169","author":"Kawai","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jbo.2022.100459_b0075","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1002\/eji.200526141","article-title":"IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL","volume":"35","author":"Kotake","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jbo.2022.100459_b0080","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1182\/blood-2006-07-037994","article-title":"B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo","volume":"109","author":"Li","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2022.100459_b0085","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jbo.2022.100459_b0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fendo.2019.00236","article-title":"Rucci N Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune Sys-tem","volume":"10","author":"Ponzetti","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jbo.2022.100459_b0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jbo.2022.100459_b0100","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1373\/clinchem.2008.105866","article-title":"New automated multiplex assay for bone turnover markers in osteoporosis","volume":"54","author":"Claudon","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.jbo.2022.100459_b0105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2017.06.020","article-title":"Eastell R Bone Turnover Markers: Use in Fracture Prediction","volume":"20","author":"Vilaca","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jbo.2022.100459_b0110","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00198-012-2049-z","article-title":"National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges","volume":"23","author":"Bauer","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.jbo.2022.100459_b0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bone.2015.11.005","article-title":"Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population","volume":"83","author":"Dai","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2022.100459_b0120","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/jbmr.2905","article-title":"Inflammatory markers and the risk of hip and vertebral fractures in men: the osteoporotic fractures in men (MrOS)","volume":"31","author":"Cauley","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbo.2022.100459_b0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2017.213","article-title":"Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity","volume":"14","author":"Walsh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbo.2022.100459_b0130","article-title":"The role of inflammatory cytokines, the RANKL\/OPG Axis, and the Immunoskeletal Interface in physiological bone turnover and osteoporosis","volume":"2013","author":"Weitzmann","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.jbo.2022.100459_b0135","first-page":"1131","article-title":"Takayanagi H RANKL signal and osteoimmunology","volume":"21","author":"Nakashima","year":"2011","journal-title":"Clin Calcium"},{"key":"10.1016\/j.jbo.2022.100459_b0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cyto.2017.05.024","article-title":"Cytokines in immunogenic cell death: applications for cancer immunotherapy","volume":"97","author":"Showalter","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.jbo.2022.100459_b0145","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","article-title":"Anderson KC Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.jbo.2022.100459_b0150","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11914-017-0381-0","article-title":"Takayanagi H Osteoimmunology in bone fracture healing","volume":"15","author":"Ono","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.jbo.2022.100459_b0155","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12979-020-00202-z","article-title":"The correlation between the Th17\/Treg cell balance and bone health","volume":"17","author":"Zhu","year":"2020","journal-title":"Immun Ageing"},{"key":"10.1016\/j.jbo.2022.100459_b0160","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/s41467-021-22875-w","article-title":"Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS\/p53 mutant lung cancers","volume":"12","author":"Peng","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jbo.2022.100459_b0165","doi-asserted-by":"crossref","first-page":"e005136","DOI":"10.1136\/jitc-2022-005136","article-title":"Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-\u0392 ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma","volume":"10","author":"Simonetti","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jbo.2022.100459_b0170","doi-asserted-by":"crossref","first-page":"e01081","DOI":"10.1002\/cti2.1081","article-title":"Smyth MJ Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity","volume":"8","author":"Dougall","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jbo.2022.100459_b0175","doi-asserted-by":"crossref","first-page":"e1431088","DOI":"10.1080\/2162402X.2018.1431088","article-title":"O'Donnell JS, et al RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jbo.2022.100459_b0180","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1200\/JCO.2013.51.3572","article-title":"McArthur GA Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma","volume":"34","author":"Smyth","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbo.2022.100459_b0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-015-0064-2","article-title":"Hanks BA Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis","volume":"3","author":"Bostwick","year":"2015","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:19:31Z","timestamp":1761941971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137422000495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S2212137422000495"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100459","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100459"}}